The latest mdcx stock price forecast suggests potential short-term volatility, with analysts eyeing a $8.90–$9.50 range driven by sector-wide momentum in biotech and upcoming earnings data. Institutional interest remains moderately positive. Medicus Pharma Ltd. (MDCX) Analyst Ratings, Estimates ... Medicus Pharma Ltd. is a biotech and life sciences company focused on accelerating the clinical development of novel and disruptive therapeutic assets. The company operates across multiple countries on three continents and is particularly engaged in developing non-invasive treatments for basal cell skin cancer through its subsidiary, SkinJect Inc., using patented dissolvable microneedle technology. The mdcx stock price forecast has lifted slightly after recent insider buying activity. Such transactions often precede positive earnings surprises in small-cap healthcare stocks.